Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Killing the Last 0.1%: Targeting Cancer Persister Cells June 15, 2026
- Phase III PrTK03 Trial Results: Aglatimagene Besadenovec (CAN-2409) Improves Survival in Localized Prostate Cancer June 15, 2026
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
Phase Ib/II Study of TYK-00540 Combined With Enzalutamide in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase Ib/II Clinical Trial of TY-302 and Abiraterone Acetate in mCRPC
/in Clinical Trial, Phase 1, Phase 2/by MaxFDA Clears First-in-Human Trial of NSD2 Inhibitor in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxUPDATE: INKmune CaRe Trial Phase 1 Results
/in Clinical Trial, Metastatic, Phase 1/by MaxPreclinical Advances in Sequencing CDK4/6 and PARP Inhibitors
/in Preclinical Research/by MaxUPDATE 2: More Data About ATNM-400 Antibody Radioconjugate Therapy
/in Antibody Radioconjugate, Preclinical Research/by MaxNew Combination Therapy Shows Potential for Treating MYC-Driven Cancers
/in Drug repurposing, Preclinical Research/by MaxPhase 1: SYN608 Targets DNA Repair in HRR-Deficient Prostate and Other Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by Max